Cited by 657Alzheimer's disease research and treatmentsCholinesterase and Neurodegenerative DiseasesDementia and Cognitive Impairment Research

The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.

NSAIDs and enantiomers of flurbiprofen target γ-secretase and lower Aβ42 in vivo

Open access

Eriksen, Jason L., Sagi, Sarah A., Smith, Tawnya E., Weggen, Sascha, Das, Pritam, McLendon, D.C., Ozols, Victor V., Jessing, Kevin W., Zavitz, Kenton H., Koo, Edward H., Golde, Todd E.·2003·Journal of Clinical Investigation

DOI 10.1172/jci18162PMC PMC166298

Open this paper in CoChat — free account Open PDF

Abstract

Epidemiologic studies demonstrate that long-term use of NSAIDs is associated with a reduced risk for the development of Alzheimer disease (AD). In this study, 20 commonly used NSAIDs, dapsone, and enantiomers of flurbiprofen were analyzed for their ability to lower the level of the 42-amino-acid form of amyloid beta protein (Abeta42) in a human H4 cell line. Thirteen of the NSAIDs and the enantiomers of flurbiprofen were then tested in acute dosing studies in amyloid beta protein precursor (APP) transgenic mice, and plasma and brain levels of Abeta and the drug were evaluated. These studies show that (a). eight FDA-approved NSAIDs lower Abeta42 in vivo, (b). the ability of an NSAID to lower Abeta42 levels in cell culture is highly predicative of its in vivo activity, (c). in vivo Abeta42 lowering in mice occurs at drug levels achievable in humans, and (d). there is a significant correlation between Abeta42 lowering and levels of ibuprofen. Importantly, flurbiprofen and its enantiomers selectively lower Abeta42 levels in broken cell gamma-secretase assays, indicating that these compounds directly target the gamma-secretase complex that generates Abeta from APP. Of the compounds tested, meclofenamic acid, racemic flurbiprofen, and the purified R and S enantiomers of flurbiprofen lowered Abeta42 levels to the greatest extent. Because R-flurbiprofen reduces Abeta42 levels by targeting gamma-secretase and has reduced side effects related to inhibition of cyclooxygenase (COX), it is an excellent candidate for clinical testing as an Abeta42 lowering agent.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1172/jci18162

Cites

52 of 52 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Glutamate neurotoxicity and diseases of the nervous system
Choi, D. W. (1988) · Neuron · doi:10.1016/0896-6273(88)90162-6 · Cited by 8,188
Alzheimer's disease: the amyloid cascade hypothesis
Hardy, J. A., & Higgins, G. A. (1992) · Science · doi:10.1126/science.1566067 · Cited by 7,484
Alzheimer's Disease: Genes, Proteins, and Therapy
Selkoe, D. J. (2001) · Physiological Reviews · doi:10.1152/physrev.2001.81.2.741 · Cited by 6,063
Inflammation and Alzheimer’s disease
Akiyama, H. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)00124-x · Cited by 4,514
Correlative Memory Deficits, Aβ Elevation, and Amyloid Plaques in Transgenic Mice
Hsiao, K., Chapman, P., Nilsen, S., Eckman, C., Harigaya, Y., Younkin, S., Yang, F., & Cole, G. (1996) · Science · doi:10.1126/science.274.5284.99 · Cited by 4,210
Secreted amyloid β–protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease
Scheuner, D., Eckman, C., Jensen, M., Song, X., Citron, M., Suzuki, N., Bird, T. D., Hardy, J., Hutton, M., Kukull, W., et al. (1996) · Nature Medicine · doi:10.1038/nm0896-864 · Cited by 2,599
Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein
Games, D., Adams, D., Alessandrini, R., Barbour, R., Borthelette, P., Blackwell, C., Carr, T., Clemens, J., Donaldson, T., Gillespie, F., et al. (1995) · Nature · doi:10.1038/373523a0 · Cited by 2,516
Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and γ-secretase activity
Wolfe, M. S., Xia, W., Ostaszewski, B. L., Diehl, T. S., Kimberly, W. T., & Selkoe, D. J. (1999) · Nature · doi:10.1038/19077 · Cited by 1,959
Statins and the risk of dementia
Jick, H., Zornberg, G. L., Jick, S. S., Seshadri, S. S., & Drachman, D. (2000) · The Lancet · doi:10.1016/s0140-6736(00)03155-x · Cited by 1,764
Increased amyloid-β42(43) in brains of mice expressing mutant presenilin 1
Duff, K., Eckman, C., Zehr, C., Yu, X., Prada, C.-M., Pérez‐Tur, J., Hutton, M., Buée, L., Harigaya, Y., Yager, D., et al. (1996) · Nature · doi:10.1038/383710a0 · Cited by 1,486

Flagged first, then by citations

Show all 52 references

Research works printed but not linked: 3

Wechter, 2000, Cancer Res., 60, 2203
Edbauer, 2003, Nat. Cell Biol., 7, 7
Murray, 2000, Clin. Pharmacol. Ther., 67, 103

Sorted by citations

Items 301–400 of 657

In vitro and in vivo profiling of CHF5022 and CHF5074
Imbimbo, B. P., Giudice, E. D., Cenacchi, V., Volta, R., Villetti, G., Facchinetti, F., Riccardi, B., Puccini, P., Moretto, N., Grassi, F., et al. (2007) · Pharmacological Research · doi:10.1016/j.phrs.2006.12.010 · Cited by 43
Pharmacological Agents Targeting γ-Secretase Increase Risk of Cancer and Cognitive Decline in Alzheimer’s Disease Patients: A Systematic Review and Meta-Analysis
Penninkilampi, R., Brothers, H. M., & Eslick, G. D. (2016) · Journal of Alzheimer’s Disease · doi:10.3233/jad-160275 · Cited by 42
Insight into the mechanism of steroidal and non-steroidal anti-inflammatory drugs
Ali, K. A., Maity, A., Roy, S. D., Pramanik, S. D., Das, P. P., & Shaharyar, M. A. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-99855-0.00004-x · Cited by 48
Therapeutic options in Alzheimer’s disease
Moreira, P. I., Zhu, X., Nunomura, A., Smith, M. A., & Perry, G. L. (2006) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.6.6.897 · Cited by 44
Quantitative analysis of amyloid- peptides in cerebrospinal fluid using immunoprecipitation and MALDI-Tof mass spectrometry
Gelfanova, V., Higgs, R. E., Dean, R. A., Holtzman, D. M., Farlow, M. R., Siemers, E., Boodhoo, A., Qian, Y., He, X., Jin, Z., et al. (2007) · Briefings in Functional Genomics and Proteomics · doi:10.1093/bfgp/elm010 · Cited by 42
Gamma-secretase modulators: a promising route for the treatment of Alzheimer's disease
Nordvall, G., Lundkvist, J., & Sandin, J. (2023) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2023.1279740 · Cited by 43
Gem-Difluoroallylation of Aryl Sulfonium Salts
Zhao, Y., Empel, C., Liang, W., Koenigs, R. M., & Patureau, F. W. (2022) · Organic Letters · doi:10.1021/acs.orglett.2c03419 · Cited by 41
EFFECT OF NAPROXEN, A NON‐SELECTIVE CYCLO‐OXYGENASE INHIBITOR, ON PENTYLENETETRAZOL‐INDUCED KINDLING IN MICE
Dhir, A., Naidu, P. S., & Kulkarni, S. K. (2005) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/j.1440-1681.2005.04233.x · Cited by 41
Current treatment of mild cognitive impairment and alzheimer’s disease
Knopman, D. S. (2006) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-996-0016-9 · Cited by 41
γ-Secretase Modulator in Alzheimer's Disease: Shifting the End
Xia, W., Wong, S. T. C., Hanlon, E. B., & Morin, P. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-120751 · Cited by 40
BACE and γ-Secretase Characterization and Their Sorting as Therapeutic Targets to Reduce Amyloidogenesis
Marks, N., & Berg, M. J. (2009) · Neurochemical Research · doi:10.1007/s11064-009-0054-1 · Cited by 38
Prevention of Alzheimer's disease
Szekely, C. A., Breitner, J. C. S., & Zandi, P. P. (2007) · International Review of Psychiatry · doi:10.1080/09540260701797944 · Cited by 41
Die Alzheimer‐Demenz: von der Pathologie zu therapeutischen Ansätzen
Jakob‐Roetne, R., & Jacobsen, H. (2009) · Angewandte Chemie · doi:10.1002/ange.200802808 · Cited by 41
Curcumin Derivatives Inhibit or Modulate Beta-Amyloid Precursor Protein Metabolism
Narlawar, R., Baumann, K., Schubenel, R., & Schmidt, B. (2007) · Neurodegenerative Diseases · doi:10.1159/000101832 · Cited by 39
Inefficient central nervous system delivery limits the use of ibuprofen in neurodegenerative diseases
Mannila, A., Rautio, J., Lehtonen, M., Järvinen, T., & Savolainen, J. (2004) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2004.10.004 · Cited by 40
A γ-Secretase Inhibitor, but Not a γ-Secretase Modulator, Induced Defects in BDNF Axonal Trafficking and Signaling: Evidence for a Role for APP
Weissmiller, A. M., Natera-Naranjo, O., Reyna, S. M., Pearn, M. L., Zhao, X., Nguyen, P. A. H., Cheng, S., Goldstein, L. S. B., Tanzi, R. E., Wagner, S. L., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0118379 · Cited by 37
Dexibuprofen prevents neurodegeneration and cognitive decline in APPswe/PS1dE9 through multiple signaling pathways
Ettcheto, M., Sánchez‐López, E., Pons, L., Busquets, O., Olloquequi, J., Beas‐Zárate, C., Pallàs, M., García, M. L., Auladell, C., Folch, J., et al. (2017) · Redox Biology · doi:10.1016/j.redox.2017.06.003 · Cited by 39
Differential actions of indomethacin: clinical relevance in headache
Summ, O., Andreou, A. P., Akerman, S., Holland, P. R., Hoffmann, J., & Goadsby, P. J. (2020) · Pain · doi:10.1097/j.pain.0000000000002032 · Cited by 39
Amyloid deposition is decreasing in aging brains
Kövari, E., Herrmann, F. R., Bouras, C., & Gold, G. (2013) · Neurology · doi:10.1212/wnl.0000000000000069 · Cited by 39
Akt / GSK3β / Nrf2 / HO-1 pathway activation by flurbiprofen protects the hippocampal neurons in a rat model of glutamate excitotoxicity
Farhat, F., Nofal, S., Raafat, E. M., & Ahmed, A. A. E. (2021) · Neuropharmacology · doi:10.1016/j.neuropharm.2021.108654 · Cited by 39
In vitro and in vivo investigation of dexibuprofen derivatives for CNS delivery
Zhang, X., Liu, X., Gong, T., Sun, X., & Zhang, Z. (2012) · Acta Pharmacologica Sinica · doi:10.1038/aps.2011.144 · Cited by 37
Concurrent blockade of free radical and microsomal prostaglandin E synthase‐1‐mediated PGE2 production improves safety and efficacy in a mouse model of amyotrophic lateral sclerosis
Shin, J. H., Lee, Y. A., Lee, J. K., Lee, Y. B., Cho, W., Im, D. S., Lee, J. H., Yun, B. S., Springer, J. E., & Gwag, B. J. (2012) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2012.07771.x · Cited by 36
Modulating Nitric Oxide Signaling in the Cns for Alzheimer’s Disease Therapy
Zhihui, Q. (2013) · Future Medicinal Chemistry · doi:10.4155/fmc.13.111 · Cited by 37
Toward prevention of alzheimers disease – Potential nutraceutical strategies for suppressing the production of amyloid beta peptides
McCarty, M. F. (2006) · Medical Hypotheses · doi:10.1016/j.mehy.2006.04.067 · Cited by 37
Treatments for Alzheimer Disease
Potyk, D. K. (2005) · Southern Medical Journal · doi:10.1097/01.smj.0000166671.86815.c1 · Cited by 37
Combination therapy in a transgenic model of Alzheimer's disease
Aytan, N., Choi, J., Carreras, I., Kowall, N. W., Jenkins, B. G., & Dedeoglu, A. (2013) · Experimental Neurology · doi:10.1016/j.expneurol.2013.10.001 · Cited by 37
Scaffold of the Cyclooxygenase-2 (COX-2) Inhibitor Carprofen Provides Alzheimer γ-Secretase Modulators
Narlawar, R., Pérez‐Revuelta, B. I., Haass, C., Steiner, H., Schmidt, B., & Baumann, K. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm0610200 · Cited by 36
Future directions in the treatment of Alzheimer?s disease
Bullock, R. A. (2004) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.13.4.303 · Cited by 36
Discovery of a Potent Pyrazolopyridine Series of γ-Secretase Modulators
Qin, J., Zhou, W. J., Huang, X., Dhondi, P., Palani, A., Aslanian, R. G., Zhu, Z., Greenlee, W. J., Cohen-Williams, M. E., Jones, N., et al. (2011) · ACS Medicinal Chemistry Letters · doi:10.1021/ml2000438 · Cited by 35
γ-Secretase inhibitors and modulators: Mechanistic insights into the function and regulation of γ-Secretase
Nie, P., Vartak, A., & Li, Y. (2020) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2020.03.002 · Cited by 36
Astrocyte subtype-specific approach to Alzheimer's disease treatment
Sarkar, S., & Biswas, S. C. (2021) · Neurochemistry International · doi:10.1016/j.neuint.2021.104956 · Cited by 35
Steroids as γ‐secretase modulators
Jung, J. I., Ladd, T. B., Kukar, T. L., Price, A. R., Moore, B. D., Koo, E. H., Golde, T. E., & Felsenstein, K. M. (2013) · The FASEB Journal · doi:10.1096/fj.12-225649 · Cited by 35
Insights into the Pathophysiology of Alzheimer’s Disease and Potential Therapeutic Targets: A Current Perspective
Kumaran, K. R., Yunusa, S., Perimal, E. K., Wahab, H. A., Müller, C. P., & Hassan, Z. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-220666 · Cited by 39
Beyond Amyloid
Lane, R. F., Shineman, D. W., Steele, J., Lee, L. H., & Fillit, H. M. (2012) · Advances in pharmacology · doi:10.1016/b978-0-12-394816-8.00007-6 · Cited by 35
The Mitochondrial Secret(ase) of Alzheimer's Disease
Young, K. J., & Bennett, J. P. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-100360 · Cited by 34
Inhibition of Amyloidogenesis by Nonsteroidal Anti-inflammatory Drugs and Their Hybrid Nitrates
Schiefer, I. T., Abdul‐Hay, S. O., Wang, H., Vanni, M., Qin, Z., & Thatcher, G. R. J. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm101450p · Cited by 34
NF-κB mediates amyloid β peptide-stimulated activity of the human apolipoprotein E gene promoter in human astroglial cells
Du, Y.-S., Chen, X., Wei, X.-L., Bales, K., Berg, D., Paul, S., Farlow, M., Maloney, B., Ge, Y.-W., & Lahiri, D. (2005) · Molecular Brain Research · doi:10.1016/j.molbrainres.2005.02.001 · Cited by 28
Inhibition of fatty acid amide hydrolase and cyclooxygenase by the N-(3-methylpyridin-2-yl)amide derivatives of flurbiprofen and naproxen
Cipriano, M., Björklund, E., Wilson, A. A., Congiu, C., Onnis, V., & Fowler, C. J. (2013) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2013.09.065 · Cited by 33
Molecular Mechanism for Various Pharmacological Activities of NSAIDS
Mizushima, T. (2010) · Pharmaceuticals · doi:10.3390/ph3051614 · Cited by 34
Substrate Sequence Influences γ-Secretase Modulator Activity, Role of the Transmembrane Domain of the Amyloid Precursor Protein
Sagi, S. A., Lessard, C. B., Winden, K. D., Maruyama, H., Koo, J. C., Weggen, S., Kukar, T. L., Golde, T. E., & Koo, E. H. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.277228 · Cited by 33
Dynamics of Aβ42 Reduction in Plasma, CSF and Brain of Rats Treated with the γ-Secretase Modulator, GSM-10h
Hawkins, J., Harrison, D. C., Ahmed, S. F., Davis, R. P., Chapman, T. D., Marshall, I., Smith, B. B., Mead, T. L., Medhurst, A. D., Giblin, G. M. P., et al. (2011) · Neurodegenerative Diseases · doi:10.1159/000324511 · Cited by 33
Validation of a nonaqueous capillary electrophoretic method for the enantiomeric purity determination of R-flurbiprofen using a single-isomer amino cyclodextrin derivative
Rousseau, A., Chiap, P., Iványi, R., Crommen, J., Fillet, M., & Servais, A. (2008) · Journal of Chromatography A · doi:10.1016/j.chroma.2008.06.006 · Cited by 33
DP‐155, a Lecithin Derivative of Indomethacin, is a Novel Nonsteroidal Antiinflammatory Drug for Analgesia and Alzheimer's Disease Therapy
Dvir, E., Elman, A., Simmons, D. A., Shapiro, I., Duvdevani, R., Dahan, A., Hoffman, A., & Friedman, J. E. (2007) · CNS Drug Reviews · doi:10.1111/j.1527-3458.2007.00014.x · Cited by 33
Dynamic Nature of presenilin1/γ-Secretase: Implication for Alzheimer’s Disease Pathogenesis
Zoltowska, K. M., & Berezovska, O. (2017) · Molecular Neurobiology · doi:10.1007/s12035-017-0487-5 · Cited by 32
Gastric Tolerability and Prolonged Prostaglandin Inhibition in the Brain with a Nitric Oxide-Releasing Flurbiprofen Derivative, NCX-2216 [3-[4-(2-Fluoro-α-methyl-[1,1′-biphenyl]-4-acetyloxy)-3-methoxyphenyl]-2-propenoic acid 4-nitrooxy butyl ester]
Wallace, J. L., Muscará, M. N., Nucci, G. D., Zamunér, S. R., Cirino, G., Soldato, P. D., & Ongini, E. (2004) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.063453 · Cited by 33
Proteolytic Antibody Light Chains Alter β-Amyloid Aggregation and Prevent Cytotoxicity
Liu, R., McAllister, C., Lyubchenko, Y. L., & Sierks, M. R. (2004) · Biochemistry · doi:10.1021/bi0492354 · Cited by 34
R-flurbiprofen improves axonal transport in the Tg2576 mouse model of Alzheimer's Disease as determined by MEMRI
Smith, K. D. B., Paylor, R. E., & Pautler, R. G. (2010) · Magnetic Resonance in Medicine · doi:10.1002/mrm.22733 · Cited by 32
Interpreting Alzheimer’s disease clinical trials in light of the effects on amyloid-β
Toyn, J. H., & Ahlijanian, M. K. (2014) · Alzheimer s Research & Therapy · doi:10.1186/alzrt244 · Cited by 31
R-flurbiprofen improves tau, but not Aß pathology in a triple transgenic model of Alzheimer's disease
Carreras, I., McKee, A. C., Choi, J., Aytan, N., Kowall, N. W., Jenkins, B. G., & Dedeoglu, A. (2013) · Brain Research · doi:10.1016/j.brainres.2013.10.025 · Cited by 35
To be or not to be toxic: aggregations in Huntington and Alzheimer disease
Slow, E., Graham, R. K., & Hayden, M. R. (2006) · Trends in Genetics · doi:10.1016/j.tig.2006.05.008 · Cited by 32
Potential of Medicinal Plants as Neuroprotective and Therapeutic Properties Against Amyloid-β-Related Toxicity, and Glutamate-Induced Excitotoxicity in Human Neural Cells
Lobine, D., Sadeer, N., Jugreet, S., Suroowan, S., Keenoo, B. S., Imran, M., Venugopala, K. N., Ibrahim, F. M., Zengin, G., & Mahomoodally, M. F. (2021) · Current Neuropharmacology · doi:10.2174/1570159x19666210412095251 · Cited by 32
Nickel-catalyzed asymmetric hydrogenation for the preparation of α-substituted propionic acids
Li, B., Wang, Z., Luo, Y., Wei, H., Chen, J., Liu, D., & Zhang, W. (2024) · Nature Communications · doi:10.1038/s41467-024-49801-0 · Cited by 31
Structural Mechanism of the Interaction of Alzheimer Disease Aβ Fibrils with the Non-steroidal Anti-inflammatory Drug (NSAID) Sulindac Sulfide
Prade, E., Bittner, H. J., Sarkar, R., del Amo, J. M. L., Althoff-Ospelt, G., Multhaup, G., Hildebrand, P. W., & Reif, B. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.675215 · Cited by 31
Molecular Basis for Allosteric Inhibition of Acid-Sensing Ion Channel 1a by Ibuprofen
Lynagh, T., Romero-Rojo, J. L., Lund, C., & Pless, S. A. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01072 · Cited by 31
The Role of PGC1α in Alzheimer’s Disease and Therapeutic Interventions
Mota, B. C., & Sastre, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115769 · Cited by 33
Alzheimer’s Disease: Lessons Learned from Amyloidocentric Clinical Trials
Soejitno, A., Tjan, A., & Purwata, T. E. (2015) · CNS Drugs · doi:10.1007/s40263-015-0257-8 · Cited by 32
Cognitive Enhancers (Nootropics). Part 2: Drugs Interacting with Enzymes
Froestl, W., Muhs, A., & Pfeifer, A. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-121537 · Cited by 31
Design, Synthesis, and Pharmacological Evaluation of a Novel Series of Pyridopyrazine-1,6-dione γ-Secretase Modulators
Pettersson, M., Johnson, D. S., Subramanyam, C., Bales, K. R., Ende, C. W. A., Fish, B. A., Green, M., Kauffman, G. W., Mullins, P. B., Navaratnam, T., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm401782h · Cited by 31
Flurbiprofen Derivatives in Alzheimer’s Disease: Synthesis, Pharmacokinetic and Biological Assessment of Lipoamino Acid Prodrugs
Pignatello, R., Pantò, V., Salmaso, S., Bersani, S., Pistarà, V., Kepe, V., Barrio, J. R., & Puglisi, G. (2007) · Bioconjugate Chemistry · doi:10.1021/bc700312y · Cited by 31
Translational Medicine Lessons from Flurizan's Failure in Alzheimer's Disease (AD) Trial: Implication for Future Drug Discovery and Development for AD
Wan, H. I., Jacobsen, J., Rutkowski, J., & Feuerstein, G. (2009) · Clinical and Translational Science · doi:10.1111/j.1752-8062.2009.00121.x · Cited by 29
Anti-inflammatory flurbiprofen nasal powders for nose-to-brain delivery in Alzheimer’s disease
Fasiolo, L. T., Manniello, M. D., Bortolotti, F., Buttini, F., Rossi, A., Sonvico, F., Colombo, P., Valsami, G. N., Colombo, G., & Russo, P. (2019) · Journal of drug targeting · doi:10.1080/1061186x.2019.1574300 · Cited by 30
Inhibitors of Rho‐kinase modulate amyloid‐β (Aβ) secretion but lack selectivity for Aβ42
Leuchtenberger, S., Kummer, M. P., Kukar, T. L., Czirr, E., Teusch, N. E., Sagi, S. A., Berdeaux, R., Pietrzik, C. U., Ladd, T. B., Golde, T. E., et al. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03553.x · Cited by 30
Amyloid β and Alzheimer disease therapeutics: the devil may be in the details
Cirrito, J. R., & Holtzman, D. M. (2003) · Journal of Clinical Investigation · doi:10.1172/jci19420 · Cited by 33
Neurosecretases provide strategies to treat sporadic and familial Alzheimer disorders
Marks, N., & Berg, M. J. (2007) · Neurochemistry International · doi:10.1016/j.neuint.2007.06.020 · Cited by 30
Pimavanserin, a 5HT2A receptor inverse agonist, rapidly suppresses Aβ production and related pathology in a mouse model of Alzheimer’s disease
Yuede, C. M., Wallace, C. E., Davis, T. A., Gardiner, W. D., Hettinger, J. C., Edwards, H. M., Hendrix, R. D., Doherty, B. M., Yuede, K. M., Burstein, E. S., et al. (2020) · Journal of Neurochemistry · doi:10.1111/jnc.15260 · Cited by 29
Flurbiprofen sodium microparticles and soft pellets for nose-to-brain delivery: Serum and brain levels in rats after nasal insufflation
Fasiolo, L. T., Manniello, M. D., Banella, S., Napoli, L., Bortolotti, F., Quarta, E., Colombo, P., Balafas, E., Kostomitsopoulos, N. G., Rekkas, D. M., et al. (2021) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2021.120827 · Cited by 31
Pyridine-derived γ-secretase modulators
Wan, Z., Hall, A., Sang, Y., Xiang, J., Yang, E., Smith, B. B., Harrison, D. C., Yang, G. Z., Yu, H., Price, H. S., et al. (2011) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2011.06.042 · Cited by 29
Developing new treatments for Alzheimer's disease: the who, what, when, and how of biomarker-guided therapies
Lyketsos, C. G., Szekely, C. A., Mielke, M. M., Rosenberg, P. B., & Zandi, P. P. (2008) · International Psychogeriatrics · doi:10.1017/s1041610208007382 · Cited by 28
Transmissibility of mouse AApoAII amyloid fibrils: inactivation by physical and chemical methods
Zhang, H., Sawashita, J., Fu, X., Korenaga, T., Yan, J., Mori, M., & Higuchi, K. (2006) · The FASEB Journal · doi:10.1096/fj.05-4890fje · Cited by 29
Presenilin/γ-secretase and inflammation
Saura, C. A. (2010) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2010.00016 · Cited by 30
A Novel Phospholipid Derivative of Indomethacin, DP-155 [Mixture of 1-Steroyl and 1-Palmitoyl-2-{6-[1-(p-chlorobenzoyl)-5-methoxy-2-methyl-3-indolyl acetamido]hexanoyl}-sn-glycero-3-phosophatidyl Choline], Shows Superior Safety and Similar Efficacy in Reducing Brain Amyloid β in an Alzheimer’s Disease Model
Dvir, E., Friedman, J. E., Lee, J. Y., Koh, J., Younis, F. M., Raz, S., Shapiro, I., Hoffman, A., Dahan, A., Rosenberg, G., et al. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.103184 · Cited by 29
Site‐specific proteolysis of cyclooxygenase‐2: A putative step in inflammatory prostaglandin E2 biosynthesis
Mancini, A. D., Jovanović, D., He, Q. W., & Battista, J. A. D. (2006) · Journal of Cellular Biochemistry · doi:10.1002/jcb.21191 · Cited by 27
Alzheimer's disease amyloid hypothesis at crossroads: where do we go from here?
Saxena, U. (2010) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2010.528285 · Cited by 28
Discovery of fused 5,6-bicyclic heterocycles as γ-secretase modulators
Qin, J., Dhondi, P., Huang, X., Mandal, M., Zhao, Z., Pissarnitski, D. A., Zhou, W. J., Aslanian, R. G., Zhu, Z., Greenlee, W. J., et al. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.12.012 · Cited by 27
Migraine Pharmacological Treatment and Cognitive Impairment: Risks and Benefits
Russo, M., Rosa, M. A. D., Calisi, D., Consoli, S., Evangelista, G., Dono, F., Santilli, M., Granzotto, A., ONOFRJ, M. C., & Sensi, S. L. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911418 · Cited by 29
Discovery of BIIB042, a Potent, Selective, and Orally Bioavailable γ-Secretase Modulator
Peng, H., Talreja, T., Xin, Z., Cuervo, J. H., Kumaravel, G., Humora, M. J., Xu, L. S., Rohde, E., Gan, L. L., Jung, M., et al. (2011) · ACS Medicinal Chemistry Letters · doi:10.1021/ml200175q · Cited by 27
Small-molecule affinity chromatography coupled mass spectrometry for drug target deconvolution
Saxena, C., Higgs, R. E., Zhen, Y., & Hale, J. E. (2009) · Expert Opinion on Drug Discovery · doi:10.1517/17460440903005565 · Cited by 27
β‐Amyloid induced effects on cholinergic, serotonergic, and dopaminergic neurons is differentially counteracted by anti‐inflammatory drugs
Hochstrasser, T., Hohsfield, L. A., Sperner‐Unterweger, B., & Humpel, C. (2012) · Journal of Neuroscience Research · doi:10.1002/jnr.23126 · Cited by 27
Anti-Alzheimer and Anti-COX-2 Activities of the Newly Synthesized 2,3′-Bipyridine Derivatives (II)
Attaby, F. A., Abdel‐Fattah, A. M., Shaif, L. M., & Elsayed, M. M. (2010) · Phosphorus, sulfur, and silicon and the related elements · doi:10.1080/10426500902917644 · Cited by 27
A new investigation for some steroidal derivatives as anti-Alzheimer agents
Abdalla, M. M., Al-Omar, M. A., Al‐Salahi, R. A., Amr, A. E. E., & Sabrye, N. M. (2012) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2012.04.012 · Cited by 27
Structural insights into the ene-reductase synthesis of profens
Waller, J., Toogood, H. S., Karuppiah, V., Rattray, N. J. W., Mansell, D. J., Leys, D., Gardiner, J. M., Fryszkowska, A., Ahmed, S. T., Bandichhor, R., et al. (2017) · Organic & Biomolecular Chemistry · doi:10.1039/c7ob00163k · Cited by 27
Processing of Amyloid Precursor Protein as a Biochemical Link Between Atherosclerosis and Alzheimers Disease
Jans, D. A., Martinet, W., van de Parre, T. J. L., Herman, A. G., Bult, H., Kockx, M. M., & Meyer, G. R. Y. D. (2006) · Cardiovascular & Haematological Disorders - Drug Targets · doi:10.2174/187152906776092695 · Cited by 27
Robust Translation of γ-Secretase Modulator Pharmacology across Preclinical Species and Human Subjects
Toyn, J. H., Boy, K. M., Raybon, J. J., Meredith, J. E., Robertson, A. S., Guss, V. L., Hoque, N., Sweeney, F., Zhuo, X., Clarke, W., et al. (2016) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.116.232249 · Cited by 26
Amyloid fibril proteomics of AD brains reveals modifiers of aggregation and toxicity
Upadhyay, A., Chhangani, D., Rao, N. R., Kofler, J., Vassar, R. J., Rincón-Limas, D. E., & Savas, J. N. (2023) · Molecular Neurodegeneration · doi:10.1186/s13024-023-00654-z · Cited by 27
Exploring the chemical space of γ-secretase modulators
Zettl, H., Weggen, S., Schneider, P., & Schneider, G. (2010) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2010.05.007 · Cited by 26
Measuring Target Effect of Proposed Disease-Modifying Therapies in Alzheimer's Disease
Bateman, R. J., & Klunk, W. E. (2008) · Neurotherapeutics · doi:10.1016/j.nurt.2008.05.009 · Cited by 26
The Amyloid Precursor Protein C-Terminal Fragment C100 Occurs in Monomeric and Dimeric Stable Conformations and Binds γ-Secretase Modulators
Botev, A., Munter, L. M., Wenzel, R., Richter, L., Althoff, V., Ismer, J., Gerling, U. I. M., Weise, C., Koksch, B., Hildebrand, P. W., et al. (2010) · Biochemistry · doi:10.1021/bi1014002 · Cited by 26
γ-Secretase Modulation with Aβ42-Lowering Nonsteroidal Anti-Inflammatory Drugs and Derived Compounds
Czirr, E., & Weggen, S. (2006) · Neurodegenerative Diseases · doi:10.1159/000095270 · Cited by 28
Regulation of Inflammation-Mediated Chronic Diseases by Botanicals
Sung, B., Prasad, S., Gupta, S. C., Patchva, S., & Aggarwal, B. B. (2012) · Advances in botanical research · doi:10.1016/b978-0-12-394591-4.00003-9 · Cited by 28
Effects of medications on plasma amyloid beta (Aβ) 42: Longitudinal data from the VITA cohort
Blasko, I., Jungwirth, S., Jellinger, K. A., Kemmler, G., Krampla, W. W., Weissgram, S., Wichart, I., Tragl, K. H., Hinterhuber, H., & Fischer, P. A. (2007) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2007.10.010 · Cited by 25
Dapsone, More than an Effective Neuro and Cytoprotective Drug
Díaz-Ruiz, A., Nader, J. A., Calderón‐Estrella, F., Mata-Bermúdez, A., Álvarez-Mejía, L., & Ríos, C. (2021) · Current Neuropharmacology · doi:10.2174/1570159x19666210617143108 · Cited by 24
TEMPO-mediated late stage photochemical hydroxylation of biaryl sulfonium salts
Zhao, Y., Yu, C., Liang, W., Atodiresei, I. L., & Patureau, F. W. (2022) · Chemical Communications · doi:10.1039/d1cc07057f · Cited by 24
Inflammation in Alzheimer’s disease
Heneka, M. T. (2006) · Clinical Neuroscience Research · doi:10.1016/j.cnr.2006.09.005 · Cited by 25
Function of Nogo‐A/Nogo‐A Receptor in Alzheimer's Disease
Xu, Y., Sun, Z., Wang, Y., Xiao, F., & Chen, M. (2015) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.12387 · Cited by 24
Brain amyloid β protein and memory disruption in Alzheimer’s disease
Xia, W. (2010) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s7460 · Cited by 24
-Secretase Modulators: Can We Combine Potency with Safety?
Gijsen, H. J. M., & Mercken, M. H. (2012) · International Journal of Alzheimer s Disease · doi:10.1155/2012/295207 · Cited by 24
Determination of flurbiprofen enantiomers in plasma using a single‐isomer amino cyclodextrin derivative in nonaqueous capillary electrophoresis
Rousseau, A., Pedrini, M., Chiap, P., Iványi, R., Crommen, J., Fillet, M., & Servais, A. (2008) · Electrophoresis · doi:10.1002/elps.200700919 · Cited by 24
Decreased axonal transport rates in the Tg2576 APP transgenic mouse: improvement with the gamma‐secretase inhibitor MRK‐560 as detected by manganese‐enhanced MRI
Wang, F., Appelkvist, P., Klason, T., Gissberg, O., Bogstedt, A., Eliason, K., Martinsson, S., Briem, S., Andersson, A. D. R., Visser, S. A. G., et al. (2012) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2012.08258.x · Cited by 24
Aβ-Degrading Proteases: Therapeutic Potential in Alzheimer Disease
Leissring, M. A. (2016) · CNS Drugs · doi:10.1007/s40263-016-0364-1 · Cited by 26
Second Generation γ-Secretase Modulators Exhibit Different Modulation of Notch β and Aβ Production
Wanngren, J., Ottervald, J., Parpal, S., Portelius, E., Strömberg, K., Borgegård, T., Klintenberg, R., Juréus, A., Blomqvist, J., Blennow, K., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.376541 · Cited by 24

Authors: Eriksen, J. L., Sagi, S. A., Smith, T. E., Weggen, S., Das, P., McLendon, D. C., Ozols, V. V., Jessing, K. W., Zavitz, K. H., Koo, E. H., & Golde, T. E.
Affiliations: Mayo Clinic (US)
University of California San Diego (US)
Corresponding author: Golde, Todd E.
ORCID: Eriksen, Jason L.
Weggen, Sascha
Das, Pritam
Koo, Edward H.
Golde, Todd E.
Venue: Journal of Clinical Investigation
Publisher: American Society for Clinical Investigation
Published: 2003-08-01
Volume: 112
Issue: 3
Pages: 440-449
ISSN: 0021-9738 (ISSN-L)
DOI: 10.1172/jci18162
PMC: PMC166298
OpenAlex: W2103071556
Cited by: 634
References: 52
Citations by year: 2026: 7 · 2025: 12 · 2024: 11 · 2023: 11 · 2022: 15 · 2021: 20 · 2020: 14 · 2019: 15 · 2018: 11 · 2017: 18 · 2016: 25 · 2015: 18 · 2014: 31 · 2013: 32 · 2012: 37
FWCI: 23.24
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: Journal of Clinical Investigation (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Funders: Mayo Foundation for Medical Education and Research
National Institutes of Health
National Institute on Aging (P01AG020206, T32AG000216)
National Institute of Neurological Disorders and Stroke (R01NS039072)
Topics: Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Keywords: nonsteroidal anti-inflammatory drugs, gamma-secretase, amyloid-beta 42, Alzheimer's disease, APP transgenic mice, ibuprofen, meclofenamic acid, dapsone, cyclooxygenase inhibition, drug repurposing
MeSH terms: Alzheimer Disease, Animals, Anti-Inflammatory Agents, Non-Steroidal, Brain, Cell Line, Female, Flurbiprofen, Humans, Meclofenamic Acid, Mice, Transgenic, Peptide Fragments, Endopeptidases, Protease Inhibitors, Stereoisomerism, Amyloid beta-Peptides, Aspartic Acid Endopeptidases, Mice, Amyloid Precursor Protein Secretases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

NSAIDs and enantiomers of flurbiprofen target γ-secretase and lower Aβ42 in vivo

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks